Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-Sure long-term follow-up after GSK3228836 response in chronic hepatitis B
NL-OMON50532Not yet recruiting
- Sponsor
- GSK
- Start
- Apr 2022
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label trial of bepirovirsen in Chronic Hepatitis B (CHB) (3 arms), sponsored by GSK. Primary endpoints: Time from achieving SVR in the previous GSK3228836 treatment study to loss of SVR and Time from NA cessation to loss of SVR. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON50532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50532.